Tag Archives: Globulin component Macrophage Activating Factor

How GcMAF Works

https://gcmaf.se/gcmaf-science/how-gcmaf-works/

Your body’s own internal medicine
Your GcMAF empowers your body to cure itself. In a healthy person your own GcMAF has 11 actions discovered so far, including two on cells, three excellent effects on the brain, and 6 on cancer. Amongst these it acts as a “director” of your immune system. But viruses and malignant cells like cancer send out an enzyme called Nagalase that prevents production of your GcMAF: that stops its 11 beneficial effects, and neutralises your immune system. So diseases become chronic, and cancer cells grow unchecked.

Minutes after a receiving a dose, 10 of the body’s actions restart. In three weeks of two GcMAF 0.25ml doses a week, your immune system is rebuilt to above normal strength. You need two doses a week for typically 24 weeks for many diseases and early cancers, up to seven one ml doses a week and a year for stage 4 cancers. Your body then takes the disease down without side effects, and successfully in 80% of cases -depending upon how well you follow the protocol under “Treatment Protocol” on this website.

What is GcMAF?
It is a human protein. One week’s GcMAF looks like a small raindrop. If properly produced it is perfectly sterile, and a most ethical course for doctors.

GcMAF is therefore a replacement therapy for those who can’t make their own. Taking GcMAF replaces the missing part of the immune system, and also acts as the body’s own internal medicine…

What does GcMAF do?
The GcMAF Conference 2013 showed GcMAF is a far more powerful molecule than thought, both in terms of the science, and doctors’ results. In stage 4 cancer, some doctors who use the full protocol, listed on “Treatment Strategies,” are saving every patient (if they have not had chemotherapy.) Success can be achieved with all tumour cancers including breast, lung, prostate, pancreatic and melanoma.

GcMAF can eradicate chronic inflammation and viral infections. It is better than antibiotics in many areas, and 25% successful with Autism, 50% or more with Chronic Herpes, Chronic Acne, Chronic cirrhosis of the liver, Chronic kidney disease, Chronic depression, Colitis, Crohn’s, Fibromyalgia, Hepatitis, Herpes, LMBBS, ME/CFS, Osteoporosis, Periodontal disease, Psoriasis and various types of Immune dysfunction including allergies. Research shows GcMAF can halt deterioration in Parkinsons, multiple sclerosis (MS), dementia and ALS, and in its role of immune system regulator, can reverse diseases that attack the immune system like Lupus and Arthritis. And is effective with wound healing. Its successful with tumour cancers, and some others.

More

Note: GcMAF is produced naturally by the body and hence like vitamin C cannot be patented unles you can make a GMO variant.

INVESTIGATION: Three days before Dr. Bradstreet was found dead in a river, U.S. govt. agents raided his research facility to seize a breakthrough cancer treatment called GcMAF

Monday, July 27, 2015
by Mike Adams, the Health Ranger
http://www.naturalnews.com/050553_Dr_Bradstreet_GcMAF_cancer_therapy.html

“…Dr. Bradstreet was working with a little-known molecule that occurs naturally in the human body. Called, “GcMAF,” this molecule has the potential to be a universal cancer cure for many people. It has also been shown to reverse autism in the vast majority of patients receiving the treatment.”

More at NaturalNews

Treatment of breast cancer patients with GcMAF

Immunotherapy of metastatic breast cancer patients with vitamin D binding protein derived macrophage activating factor (GcMAF)
http://science.naturalnews.com/2008/4030259_Immunotherapy_of_metastatic_breast_cancer_patients_with_vitamin_D_binding.html
Macrophages treated in vitro with GcMAF (100 pg/ml) are highly tumoricidal to mammary adenocarcinomas. Efficacy of GcMAF for treatment of metastatic breast cancer was investigated with 16 nonanemic patients who received weekly administration of GcMAF (100 ng). As GcMAF therapy progresses, the MAF precursor activity of patient Gc protein increased with a concomitant decrease in serum Nagalase. Because of proportionality of serum Nagalase activity to tumor burden, the time course progress of GcMAF therapy was assessed by serum Nagalase activity as a prognostic index. These patients had the initial Nagalase activities ranging from 2.32 to 6.28 nmole/min/mg protein. After about 16-22 administrations (approximately 3.5-5 months) of GcMAF, these patients had insignificantly low serum enzyme levels equivalent to healthy control enzyme levels, ranging from 0.38 to 0.63 nmole/min/mg protein, indicating eradication of the tumors. This therapeutic procedure resulted in no recurrence for more than 4 years.